Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical

Cephalon/Alkermes Vivitrex User Fee Date Extended

This article was originally published in The Pink Sheet Daily

  • News

Executive Summary

FDA has extended the user fee date for Cephalon's and Alkermes' alcohol dependency therapy Vivitrex (naltrexone) by three months to Dec. 30, the companies announced Sept. 20

You may also be interested in...



Alcohol Dependence Treatment Vivitrol “Approvable”

Alkermes/Cephalon expect to launch the renamed once-monthly naltrexone injection in the second quarter.

Alcohol Dependence Treatment Vivitrol “Approvable”

Alkermes/Cephalon expect to launch the renamed once-monthly naltrexone injection in the second quarter.

Alkermes Submits Vivitrex NDA

Alkermes' Vivitrex would be the first alcohol dependence treatment available in a once-monthly injection if FDA approves the NDA submitted March 31

Table

View full table

Topics

Tags:
BioPharmaceutical
Latest Headlines

Generic Or Innovator? Sandoz Sues CMS Over Potential Change In Rebate Classification

US FDA Gene Therapy Accelerated Approval Guidance Will Describe ‘Buckets’ Of Use Scenarios

FTC Early Findings In PBM Investigation Coming By Mid-Summer, Chair Kahn Says

New EU Filings

See All
UsernamePublicRestriction

Register

PS062910

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By